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Human dental pulp stem cells (hDPSCs), selected from the stromal-vascular fraction of
dental pulp, are ecto-mesenchymal stem cells deriving from neural crests, successfully
used in human bone tissue engineering. For their use in human therapy GMP procedures
are required. For instance, the use of fetal bovine serum (FBS) is strongly discouraged
in clinical practice due to its high risk of prions and other infections for human health.
Alternatively, clinical grade sera have been suggested, including the New Zealand FBS
(NZ-FBS). Therefore, the aim of this study was to evaluate the behavior of hDPSCs
expanded in culture medium containing NZ-FBS. Since it was widely demonstrated
hDPSCs display relevant capabilities to differentiate into osteogenic and angiogenic
lineages, we performed a comparative study to assess if these features are also retained
by cultivating the cells with a safer serum never tested on this cell line. hDPSCs were
grown using NZ-FBS and conventional (C-FBS) for 7, 14, and 21 days, in both 2D
and 3D cultures. Growth curves, expression of bone-related markers, calcification and
angiogenesis were evaluated. NZ-FBS induced significant cell growth with respect to
C-FBS and promoted an earlier increase expression of osteogenic markers, in particular
of those involved in the formation of mineralized matrix (BSP and OPN) within 14 days. In
addition, hDPSCs cultured in presence of NZ-FBS were found to produce higher mRNA
levels of the angiogenic factors, such as VEGF and PDGFA. Taken together, our results
highlight that hDPSCs proliferate, enhance their osteogenic commitment and increase
angiogenic factors in NZ-FBS containing medium. These features have also been found
when hDPSC were seeded on the clinical-grade collagen I scaffold (Bio-Gide®), leading
to the conclusion that for human therapy some procedures and above all the use of
GMP-approved materials have no negative impact.
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INTRODUCTION
There is an increasing interest in the regeneration of organs
and tissues damaged by diseases, trauma or aging. In human
regeneration, the use of autologous and allogeneic stem cells
isolated from various tissues of adult individuals has fewer ethical
problems than the use of embryonic stem cells (Caplan, 2007;
Ferro et al., 2012). An easily accessible source of mesenchymal
stem cells is the dental pulp, which is a stromal, fibrous, highly
vascularized structure located in the inner part of the tooth
(d’Aquino et al., 2007). Stem cells from dental follicles and human
dental pulp stem cells (hDPSCs) express several transcription
factors that are involved in the maintenance of self-renewal
and pluripotency such as Sox2 and Nanog (d’Aquino et al.,
2011), and specific mesenchymal stem cell markers such as
CD90 (Ponnaiyan et al., 2012) and CD34, used for the first
time by Laino et al. to isolate a population of stromal stem
cells of neural crest origin (Laino et al., 2005). Under definite
culture conditions, hDPSCs differentiate into numerous cell
types, including osteogenic, adipogenic, neurogenic, and neural
crest-derived cells (Almushayt et al., 2006; Zhang et al., 2006;
Arthur et al., 2008; Paino et al., 2010). Several studies have shown
that hDPSCs can be successfully used in clinical practice as a
new therapeutic tool for healing bone defects (d’Aquino et al.,
2009; Mitsiadis et al., 2011; Giuliani et al., 2013) since it was
demonstrate that DPSCs are self-committed to osteogenic and
angiogenic differentiation (d’Aquino et al., 2007).
However, various important issues have been addressed
concerning the clinical use of hDPSCs, namely the generation
of an adequate number of cells in a short period of time; the
characterization of cells at all stages of culture before their use
in clinic (Tirino et al., 2012); and the development of safe-for-
human-use materials for the isolation and maintenance of cells
selected for therapy (Desiderio et al., 2014). For these reasons, it
is necessary to standardize procedures and good manufacturing
practice (GMP) protocols for the culture of the stem cells for
clinical use (La Noce et al., 2014). To this end, the development
of international standards for the production of hDPSCs, in
accordance with GMP, holds a paramount importance.
In this context, physical and chemical factors play a pivotal
role since they can influence the cell culture conditions and,
therefore, the cells’ fate. Stem cells display different behaviors and
answers in culture and it is extremely complex to obtain similar
stem cell stocks following a standard protocol. Moreover, the
serum added to basic medium may contain growth factors and
nutrients that mimic the extracellular environment, which may
be crucial for cell proliferation and differentiation. Usually, cells
are cultured in media containing animal-origin sera which are
not recommended for clinical practice because of concerns about
human safety. In fact, viruses, prions, mycoplasma or any other
animal pathogen could contaminate the sera. Bovine sera are
the most commonly used and, in particular, fetal bovine serum
(C-FBS) has become the standard supplement for cell culture
media. It is a cocktail of most of the factors required for cell
proliferation and maintenance, and thus is an almost universal
growth supplement. FBS sourced from New Zealand (NZ-FBS)
is a valid bovine serum as it offers greater safety due to the fact
that New Zealand has the fewest reported bovine diseases in the
world for its geographically isolation. Indeed, one of the benefits
of this isolation is that New Zealand has been determined to be
free from BSE and FMD.
Additionally, the use of DPSCs in clinical applications requires
a support system. The choice of scaffolds for tissue engineering
is rather critical due to the large amount of existing variables
and the GMP procedures require that these scaffolds are clinical-
grade, ready for human use (Naddeo et al., 2015; Mele et al.,
2016).
In this study, two different sera have been assayed and
compared, namely the commonly used C-FBS, and a more
controlled FBS, originating from New Zealand (NZ-FBS), that is
GMP-approved. In addition, the influence of two different sera
on a three-dimensional (3D) culture of hDPSC in vitro, using a
commercially available clinical-grade collagen I bioscaffold, the
Bio-Gide R© (Geistlich, Wolhusen, CH), has been assessed.
MATERIALS AND METHODS
Human Dental Pulp Extraction and Cell
Culture
Human dental pulps were extracted from teeth of healthy adults
(21–38 years of age). Prior to the extraction, each subject (n =
40) was checked for systemic and oral infections or diseases.
Only patients undergoing a third molar or supernumerary
tooth extraction were interviewed and enlisted. All subjects
signed the Ethical Committee (SecondUniversity Internal Ethical
Committee) consent brochure before being enrolled. Every
subject was pretreated for a week with professional dental
hygiene. The dental crown was covered with 0.3% chlorhexidine
gel (Forhans, New York, USA) for 2min prior to the extraction.
Dental pulp was obtained with a dentinal excavator or a
Gracey curette. The pulp was delicately removed and immersed
for 1 h at 37◦C in a digestive solution composed of 3mg/ml
type I collagenase and 4mg/ml dispase in phosphate buffered
saline (PBS) containing 40mg/ml gentamicin. Once digested,
the solution was filtered through 70 µm Falcon strainers
(Becton & Dickinson, Franklin Lakes, NJ, USA). Cells were
cultured in basal growth medium consisting of Dulbecco’s
modified Eagle’s medium (DMEM) with 100 U/mL penicillin,
100mg/mL streptomycin and 200mM L-glutamine (all from
GIBCO, Monza, Italy), supplemented with the two sera to get
the different culture conditions: (a) 10% fetal bovine serum (C-
FBS; GIBCO, Monza, Italy), and (b) 10% New Zealand origin
FBS (NZ-FBS; SAFC Biosciences). Cultures were maintained in
a humidified atmosphere under 5% CO2 at 37
◦C. Media were
changed twice a week. The analyses were conducted at 7, 14, and
21 days of culture.
Growth Analysis
Cells in the two different culture media were plated at a density of
50,000 cells/well in 6-well plates and at a density of 100,000 cells
in T25 flasks. The cells were harvested and re-suspended in PBS.
An aliquot of cell suspension was diluted with 0.4% trypan blue
(Sigma-Aldrich, Milan, Italy), pipetted onto a hemocytometer
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and counted under a microscope. The number of viable cells for
each experimental condition was counted and represented on a
linear graph. The doubling time (DT) was determined from the
growth curves or by using the formula.
DT = (t − t0) log 2/(logN− logN0)
where t and t0 were the times at which the cells were counted, and
N and N0 were the cell numbers at times t and t0, respectively.
FACs Analysis
Flow cytometry analyses were performed on hDPSCs cultured
in medium supplemented with C-FBS or NZ-FBS at first
passage of culture. Cells were incubated with FITC-conjugated
anti-CD90, PerCP-Cy5.5-conjugated anti-CD105, APC-Cy7-
conjugated anti-CD45 (all purchased from BD Pharmingen,
San Diego, CA), and PE-conjugated anti-CD34 (Miltenyi
Biotech, Calderara di Reno, Bologna, Italy) for phenotypic
characterization; and anti-Bone sialoprotein (BSP) (Abcam,
Cambridge, UK), anti-CFS-conjugated anti-Osteopontin
(OPN), PE-conjugated anti-Osteocalcin (OC) (both from R&D
Systems, Minneapolis, MN) and PerCP-Cy 5.5-conjugated anti-
Nanog (BD Pharmingen, Milan, Italy) to evaluate osteogenic
differentiation and mesenchymal stemness. hDPSCs were sorted
by CD34 expression. The purity of sorting was 90%. As negative
controls, cells were stained with an isotype control antibody.
After incubation with the antibody, cells were resuspended
in PBS and analyzed with a FACS ARIA III (BD Biosciences,
San Jose, CA). For intracellular staining of Osteocalcin,
Osteopontin and Nanog, cells were processed using Fix & Perm
Kit (Invitrogen, Milan, Italy) following the manufacturer’s
guidelines. All data were analyzed using FCS express version 3
(De Novo Software, Glendale, CA).
RNA Isolation and qRT-PCR
Total RNA was extracted from hDPSCs after 7, 14, and 21 days
of culture in DMEM supplemented with 10% C-FBS or 10%
FBS New Zealand, using an AMBION kit (Life Technologies
Italia, Monza, Italy) following the manufacturer’s instructions.
RNA was treated with DNase (Promega, Milan, italy) to exclude
DNA contamination and stored at −80◦C. cDNA synthesis was
carried out from total RNA (1µg) using VILO SUPERSCRIPT
(Invitrogen, Monza, Italia,). Samples were analyzed using real-
time quantitative PCR. PCR reactions were performed using
StepOne Thermocycler (Applied Biosystems, Monza, Italy) and
the amplifications were done using the SYBR Green PCR
Master Mix (Applied Biosystems, Monza, Italy). The thermal
cycling conditions were: 50◦C for 2min followed by an initial
denaturation step at 95◦C for 2min, 40 cycles at 95◦C for 30 s,
60◦C for 30 s and 72◦C for 30 s. Real-time PCR was performed
using the primer sequences shown in Table 1. The experiments
were carried out in triplicate for each data point. Gene expression
was normalized to GAPDH considered as internal control.
Alizarin Red Staining and Quantification
After 21 days of culture in the different sera, osteogenic
differentiation was evaluated by Alizarin Red staining to visualize
calcium-rich deposits produced by the cells. The samples were
TABLE 1 | Primers for real time RT-PCR.
Gene Primer sequence Ta (◦C)
GAPDH Fw: GGAGTCAACGGATTTGGTCG 57
Rev: CTTCCCGTTCTCAGCCTTGA
CD90 Fw: CCCAGTGAAGATGCAGGTTT 60
Rev: GACAGCCTGAGAGGGTCTTG
RUNX2 Fw: CACTCACTACCACACCTACC 52
Rev: TTCCATCAGCGTCAACACC
CD34 Fw: TCAAATGTTCAGGCATCAGAG 56
Rev: TCAGGTCAGATTGGTGCTT
NANOG Fw: TTCAGTCTGGACACTGGCTG 58
Rev: CTCGGTGATTAGGGTCCAAC
BGLAP (OSTEOCALCIN) Fw: CTCACACTCCTCGCCCTATTG 57
Rev: CTTGGACACAAAGGCTGCAC
SPP1 (OSTEOPONTIN) Fw: GCCGAGGTGATAGTGTGGTT 58
Rev: TGAGGTGATGTCCTCGTCTG
IBSP Fw: GGGCAGTAGTGACTCATCCG 58
Rev: TTCTCAGCCTCAGAGTCTTCA
SP7 (OSTERIX) Fw: TCCTCCCTGCTTGAGGAGGA 60
Rev: AGTCCCGCAGAGGGCTAGAG
CXCR4 Fw: CCTATGCAAGGCAGTCCATGT 57
Rev: GGTAGCGGTCCAGACTGATGA
ITGB1 (INTEGRIN-BETA1) Fw: CATCTGCGAGTGTGGTGTCT 57
Rev: GGGGTAATTTGTCCCGACTT
VEGF Fw: TGACAGGGAAGAGGAGGAGA 59
Rev: CGTCTGACCTGGGGTAGAGA
PDGFA Fw: ACACGAGCAGTGTCAAGTGC 60
Rev: GGCTCATCCTCACCTCACAT
washed twice in PBS, fixed with 4% paraformaldehyde (PFA)
in PBS for 30min at 4◦C, and stained with Alizarin Red
solution (2%, pH 4.2; Sigma Aldrich, Milan, Italy) for 20min
at room temperature. Stained cells were extensively washed
with deionized water to remove any nonspecific precipitation.
Micrographs were taken with a microscope Eclipse TE2000-S
(Nikon, Firenze, Italy) and a Nikon camera (Nikon, Firenze,
Italy).
For the quantification of Alizarin Red S staining, 4ml 10%
(vol/vol) acetic acid was added to each well and the plate was
incubated at room temperature for 30min under gentle agitation.
The monolayer was scraped off the plate and transferred to a
1.5ml microcentrifuge tube after adding 1ml of 10% (vol/vol)
acetic acid. After vortexing for 30 s, the slurry was overlaid with
1.25ml mineral oil (Sigma-Aldrich, St. Louis, MO), heated to
85◦C for 10min, and transferred to ice for 5min. The slurry
was then centrifuged at 20,000 g for 15min, and 500µl of the
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supernatant then removed to a new 1.5ml microcentrifuge tube.
200µl of 10% (vol/vol) ammonium hydroxide was added to
neutralize the acid. Absorbance of aliquots (150 µl) of the
supernatant was measured in triplicate at 405 nm in a 96-well
format.
Quantification of Osteocalcin in
Supernatant
Osteocalcin levels were evaluated in the culture supernatants of
hDPSCs at different time and tested sera by a solid phase Enzyme
Amplified Sensitivity Immunoassay (EASIA) kit (Invitrogen,
Monza, Italy). Standards and samples were analyzed in duplicate.
The assay was performed according to the manufacturer’s
protocols. The absorbance of each well was read at 450
nm and the concentration of Osteocalcin was determined by
interpolation from the standard curve.
Cell Seeding on Bio-Gide® Collagen
Scaffolds
In order to both better analyze the hDPSCs performances
in presence of the two sera, and understand the DPSCs’s
potential differentiation capabilities, we challenged these stem
cells in a 3D culture system, in order to determine to what
extent these cells were capable of differentiating toward bone
and vessel progenitors, in presence of GMP-approved or FBS
serum. For this purpose, hDPSCs were seeded onto BioGide R©
(Geistlich Pharma AG, Switzerland), a clinical-grade collagen I
reabsorbable bilayer membrane composed of a superior thick and
an inferior smooth surface. The scaffold’s membrane is made of
a natural collagen I without further cross-linking: the superior
thick and porous surface allows the adhesion of osteoblasts on
the surface, whereas the dense and smooth surface hinders cells
to both adhere and penetrate inside it.
This scaffold, commercially used in dentistry, has a low
antigenicity and excellent biocompatibility.
The membranes were cut under sterile conditions into pieces
of equal size (5 × 5mm). Scaffolds were placed in 6-well-plates
and a cell suspension of 1 × 106 cells/ 200µl of medium was
pipetted onto the top (thick and porous surface) of each piece.
Cells were allowed to adhere under a humidified atmosphere at
37◦C and 5% CO2 for 4 h. The seeded scaffolds were then placed
in tubes containing DMEM supplemented with the two different
sera (C-FBS andNZ-FBS) for 30 days in an incubator at 37◦C and
5% CO2. Media were changed twice a week.
Cryostat Sectioning
After 3D culture, samples were fixed in 4% paraformaldehyde
(PFA) and cryoprotected overnight at 4◦C by immersion in a
30% (wt/vol) sucrose solution before being embedded in Tissue-
Tek R© O.C.T. Compound (Tissue-Tek; Sakura Finetek, Torrance,
FIGURE 1 | (A) Characterization of DPSCs at the first passage of culture: cytometric analysis of CD90, CD105, CD45, and CD34 markers in DPSCs. Histograms
represent the number of cells (y axis) and the fluorescence intensity (x axis) relative to unstained control cells (dot line) and cells marked with specific antibodies against
surface proteins (solid line). (B) Growth curve of DPSCs cultured in DMEM + 10% of standard FBS and in DMEM + 10% of New Zealand FBS up to 72 h. (C) Growth
performance was studied up to 21 days. **p < 0.001.
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CA,) and frozen. Sections were cut 5-µm thick with a cryostat at
−20◦C and then processed for immunostaining.
Immunohistochemistry/
Immunofluorescence Analysis
hDPSCs cultured in 24-well plates were fixed with 4% PFA in
PBS for 20min at room temperature. After washing in PBS,
samples were permeabilized with 0.1% Triton X-100 for 5min
and blocked with 1% BSA in PBS. Incubation with primary anti-
OC antibody (sc-30044 Santa Cruz) was performed overnight at
4◦C. Primary antibody was revealed using a FITC-conjugated
anti-rabbit IgG secondary antibody. Nuclei were stained with
Hoechst.
Frozen sections were stained by Hematoxylin and Eosin or
permeabilized with 0.1% Triton X-100 for 15min. Incubation
with primary antibodies anti-OPN (ab8448 Abcam, Cambridge,
UK), anti-OC (sc-30044 Santa Cruz), and anti-VEGF (ab39250
Abcam Cambridge, UK) was performed overnight at 4◦C. FITC
conjugated secondary antibody to rabbit IgG was used to reveal
primary antibodies. Micrographs were taken with a microscope
EVOS FL Cell Imaging System (Life Technologies).
Statistical Analysis
Values are shown as the mean ± S.E.M. of measurements of
at least three independently performed experiments to avoid
TABLE 2 | Doubling time of DPSCs under different culture conditions.
Culture conditions Doubling Time (hours) P-value
DMEM + 10% C-FBS 126 ± 12 P < 0.001
DMEM + 10% NZ-FBS 94 ± 7 P < 0.005
possible variation of cell cultures. Student’s t-test was employed,
and p< 0.05 was considered to be statistically significant.
RESULTS
Characterization of hDPSCs by Flow
Cytometric Analysis
At the first culture passage, cells were characterized by
evaluating the expression of CD90, CD105, CD45, and CD34
using cytometric analysis. Cells were all positive for the
mesenchymal markers CD90 and CD105, and negative for CD45.
Approximately 20% of cells were positive for CD34 (Figure 1A).
Then cells were sorted by CD34.
Evaluation of Cell Proliferation after Sera
Treatment
Cell proliferation under the different conditions was evaluated at
24, 48, and 72 h (Figure 1B) and at 7, 14, and 21 days (Figure 1C)
of culture. To this purpose, equal numbers of cells were initially
plated and the relative time of duplication was assessed. Either
C-FBS and NZ-FBS promoted hDPSC proliferation. However,
there were lower numbers of cells in bovine-origin sera compared
with NZ-FBS, a difference already detectable at 48 h (Figure 1B).
NZ-FBS stimulated earlier cell duplication with a reduction
in the doubling time to less than a half of that of NZ-FBS
(Table 2).
Phenotypic Characterization of DPSCs
during Cell Culture
In order to evaluate the effect of different sera on the expression
of stemness and osteogenic markers, a flow cytometric assay at
different days of culture for CD34, NANOG, CD90, BSP, and
FIGURE 2 | Cytometric analysis for stemness markers (A–C), and osteogenic markers (D,E) in DPSCs.
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FIGURE 3 | Gene expression analysis for osteogenic markers (A–E), and stemness markers (F–H) in DPSCs. *p < 0.05; **p < 0.001.
OPN, was performed (Figures 2A–E). Levels of the stromal-
vascular antigen CD34 decreased up to day 21 (Figure 2A)
in both sera. Expression of the stemness marker NANOG
also decreased, although its protein level was higher at 7
days of culture in NZ-FBS (Figure 2B). All hDPSCs expanded
with C-FBS and NZ-FBS, showed positivity (>98%) for the
mesenchymal marker CD90 (Figure 2C).
The expression of osteogenic markers BSP and OPN did not
show substantial differences during culture time using both sera
(Figures 2D,E).
Further investigations on osteogenic features and the
maintenance of stemness were also performed using a
quantitative RT-PCR for RUNX2, SP7 (OSTERIX), IBSP,
BGLAP(OSTEOCALCIN), SPP1 (OSTEOPONTIN), CD90,
NANOG, and CD34 at 7, 14, and 21 days of culture
(Figures 3A–H). The expression of RUNX2, the master
transcription factor of osteogenic differentiation, was higher in
FBS-NZ at 7 days of culture and then decreased at 14 and 21
days in both sera without significant differences (Figure 3A).
SP7 mRNA, another transcription factor involved in osteogenic
differentiation, showed an increase only at 7 days of culture
(Figure 3B).
mRNA levels of IBSP, BGLAP and SPP1 increased in cells
cultured with FBS-NZ starting from 7 days (Figures 3C–E).
The mRNA levels of CD90 were comparable in all the
experimental conditions (Figure 3F). NANOG was always
expressed but decreased during culture time as well as CD34
mRNA (Figures 3G,H).
Intracellular Localization of Osteocalcin,
Evaluation of Mineralization, and
Osteocalcin Secretion
Immunoreactivity for OC was strongest and distributed
throughout the cell in hDPSCs cultured with NZ-FBS at 21
days of culture (Figure 4B). hDPSCs cultured with C-FBS were
only weakly positive for OC that was mostly localized in the
perinuclear region (Figure 4A).
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FIGURE 4 | Immunofluorescence analysis for osteocalcin in DPSCs cultured with C-FBS (A) and NZ-FBS (B). Scale bar = 10µm. Alizarin red analysis of
DPSCs cultured with C-FBS (C) and NZ-FBS (D). Scale bar = 100µm. (E) Alizarin Red Quantification. (F) Osteocalcin concentration with C-FBS and NZ-FBS. **p <
0.001.
Alizarin red staining was used to evaluate calcium-rich
deposits after 21 days of culture (Figures 4C,D). Calcified
nodules were absent in cultures with C-FBS (Figure 4C)
but small areas of staining were evident, whereas mineral
deposition was observed in cultures with NZ-FBS (Figure 4D).
This observation was confirmed by Alizarin red quantification
(Figure 4E).
Moreover, we determined the concentration of OC in the
culture supernatants after 21 days. A significant difference
was observed between the two tested sera (Figure 4F). In
FBS-NZ the amount of osteocalcin in the medium was
very low.
Homing, Chemotaxis and Evaluation of
Angiogenesis
In order to evaluate a possible effect of FBS-NZ on DPSCs
homing and chemotaxis, we assessed the expression of ITGB1
(INTEGRIN-β1) and CXCR4. ITGB1 mRNA showed a slight
increase at 7 days of culture with NZ-FBS, but then remained
almost unchanged in the two different tested sera (Figure 5A).
Frontiers in Physiology | www.frontiersin.org 7 August 2016 | Volume 7 | Article 354
Spina et al. hDPSCs with Standard and NZ Sera
FIGURE 5 | Real time PCR for genes involved in chemotaxis and cell adhesion. In (A,B) are respectively shown expression of Integrin beta 1 (Intβ1) and
chemokine receptor 4 (CXCR4) mRNA in DPSCs. Real time PCR for genes involved in angiogenesis: VEGF (C) and PDGFA (D) mRNA levels in DPSCs. All results
were normalized to GAPDH expression. **p < 0.001.
The expression of CXCR4 was more induced by NZ-FBS at 7
and 14 days of culture, and drastically decreased at 21 days
(Figure 5B).
The expression of VEGF and Platelet-derived growth
factor A (PDGFA) mRNAs in hDPSCs was also evaluated
after numerous days of culture (Figures 5C,D). The VEGF
expression was significantly promoted by NZ-FBS at 14 and
21 days of culture (Figure 5C); the expression of PDGFA
gene was higher in NZ-FBS samples only at 14 days of
culture, then decreased (Figure 5D). hDPSCs were negative for
PDGFB mRNA in all the experimental conditions (data not
shown).
3D Culture Experiments
The results of 3D cultures are shown in Figure 6. In this figure,
the cross section of the scaffold is depicted in IA: it is made of
collagen I fibers surrounded on the two sides by amembrane (one
thick and porous and another smooth).
Challenging hDPSCs with this scaffold, in presence of the
two sera, hDPSCs displayed on the scaffold’s surface constituting
a cell monolayer as shown in Figure 6IB. Specifically,
through the use of specific antibodies for osteo-angiogenesis,
we found that cells expressed all the markers, including
OPN, OC, VEGF (Figures 6IIA–F), through the whole cell
layer.
In particular, using NZ-FBS in cultures, DPSCs were found to
be noticeably positive for the said markers of bone and vessels
(Figures 6IIB,D,F).
DISCUSSION
The use of animal sera for stem cell cultures may be unsafe
for human cell-based therapies as they may contain factors or
pathogens that could be transferred to patients or cause immune
rejection during cell transplantations (Mackensen et al., 2000;
Sundin et al., 2007).
In the present study, a GMP-approved serum was compared
with a commercial fetal bovine serum during isolation and
expansion of hDPSCs in vitro.
Freshly isolated hDPSCs, were characterized and found to be
positive for common mesenchymal stem cells markers. Later,
hDPSCs phenotype was characterized during culture and the
differences in cell proliferation, stemness, and osteogenic features
were assessed.
In this study it has been shown that NZ-FBS induced
significant cell growth with respect to C-FBS. The expression of
CD90 marker remained unchanged throughout all experimental
conditions, indicating that these cells maintained the
mesenchymal lineage, whereas the expression of stemness
markers CD34 and NANOG decreased with time, as expected.
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FIGURE 6 | I: (A) Cross section of the scaffold; (B) hDPSCs on the scaffold’s surface constitute a cell monolayer. Scale bar = 400µm. II: Immunofluorescence
analysis of specific antibodies for osteo-angiogenesis, (OPN, OC, VEGF) in cells seeded on scaffolds and cultured with C-FBS (A,C,E) and NZ-FBS (B,D,F). Scale
bar = 200µm.
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This suggested that DPSCs progressively lose their stem cell
property during in vitro expansion. In addition, we observed
that the use of NZ-FBS promoted an earlier increase expression
of osteogenic markers, in particular of those involved in the
formation of mineralized matrix (BSP and OPN) within 14
days as well as evidenced by Alizarin Red staining. Moreover,
the osteocalcin expression in 2D culture, during time, showed
a significant increase: BGLAP mRNA was higher with NZ-
FBS compared with C-FBS cultures, and its protein detected
by immunofluorescence, was more evident and distributed
throughout the cytoplasm. In addition, we noted that the
lowest amount of osteocalcin was found in medium recovered
from cells cultured with NZ-FBS. This suggested that released
osteocalcin can bind to the extracellular matrix and guide
hydroxyapatite to form mineralized nodules (Neve et al.,
2013).
RUNX2 and SP7 are the key transcription factors initiating
and regulating the osteogenesis, respectively (Zhou et al.,
2010; Bruderer et al., 2014). NZ-FBS induced a slight increase
in RUNX2 and SP7 at 7 days of culture. In summary, NZ-
FBS induced a positive effect on DPSCs culture allowing an
earlier commitment to differentiation toward osteogenic fates,
when compared with C-FBS. The differences in osteogenic
potential were detectable already at 7 days of culture,
when NZ-FBS enhanced the expression of bone-related
markers.
When a tissue or organ is damaged, several mechanisms
may contribute to the success of wound repair, both under
physiological conditions and after administration of stem
cells. Angiogenesis, chemotaxis, homing, and engraftment are
crucial in equal measure to allow the repair of an injured
tissue by stem cells. Chemotactic stimuli recruit various
cell types to the injury site. The interaction between the
chemokine SDF1 and its receptor CXCR4 expressed on
the hDPSCs’ surface is a key factor in the recruitment of
these cells to the damaged area (Jiang et al., 2008; Kim
et al., 2013). The use of both sera induced an increase in
CXCR4 expression on hDPSCs within 14 days of culture
but this was more evident in cells expanded with NZ-
FBS. In addition to cell migration, cell-matrix, and cell-
cell interactions play essential roles in tissue reparation. The
expression of surface molecules such as integrins may influence
the maintenance of stemness, cell proliferation and changes
during the differentiation process. Our findings show that there
are no substantial differences in the effects of integrins between
the various sera, suggesting that culture conditions did not
interfere with cell adhesion.
When an injury, such as a fracture occurs, the vasculature is
compromised and hinders the supply of nutrients and oxygen to
the site of the lesion. Angiogenesis is a crucial process for bone
healing. During tissue reparation, themigration and organization
of endothelial cells into capillary tubes is regulated by a paracrine
and autocrine action of VEGF (Lamalice et al., 2007). When
the damaged tissue involves bone, the cells located in its inner
part have a limited blood and oxygen supply. This major issue
must necessarily be overtaken in order to obtain good results in
clinical practice. At this purpose, we considered the expression
of VEGF and PDGFA. hDPSCs cultured in presence of NZ-FBS
were found to produce highermRNA levels of the said angiogenic
factors.
In addition, hDPSC’s capabilities in culture were examined by
evaluating a 3D environment. To this aim, we seeded hDPSCs on
the Bio-Gide scaffold.
This scaffold was chosen because of the following features:
it is made of collagen I, the physiological collagen of bone; it
is clinically approved and commonly used mainly in order to
constitute a biological barrier between bone and soft tissues.
In fact, during surgical procedures such as craniofacial and
orthopedic surgeries, the correct growth of both bone and
the surrounding connective tissue must be ensured. For this
purpose, the aforementioned scaffold has been manufactured
as a biological barrier to cell penetration on one of the two
surfaces: one thick and porous (upper) and another smooth
(lower), generally facing the soft tissues. The thick surface
allows the ingrowth of bone-forming cells, whereas the latter
prevents the ingrowth of fibrous tissue into the bone defect.
Therefore, cells are not allowed to penetrate it and they cannot
invade the re-absorbable scaffold. Thereby, the cells remain
on the surface and our aim, devoted to observe the level of
differentiation under the different sera, was better evidenced
by observing them at the surface of the scaffold, without other
possible interferences. Finally, based on the clinical observations,
this scaffold is fully biocompatible. As evidenced by the results,
hDPSCs on the scaffold’s surface strongly expressed OC, OPN
and VEGF in all the cases above all in presence of NZ-FBS. Taken
together, our results strongly indicate that NZ-FBS (clinical
grade) has a positive effect on replicative potentials and self-
commitment of hDPSCs. Therefore, NZ-FBS can be considered
a reliable tool for cell-based treatments in autologous grafts and
GMP conditions for bone repair and regeneration. Under these
conditions, hDPSCs retain their features directing toward osteo-
angiogenesis lineage, which represents the gold standard in order
to obtain a well-vascularized bone.
In addition, the use of sera belonging to controlled animals
could overcome the problems related to GMP standards,
that require developing well-defined culture conditions,
guaranteeing the maintenance of stem cell multipotency and/or
differentiation.
AUTHOR CONTRIBUTIONS
MN: Designed the study, performed the experiments, wrote the
manuscript and approved it. AS, RM, DL, LL, AR: Performed
experiments, collected data. TM: Designed the experiment,
approved the manuscript.
ACKNOWLEDGMENTS
This study was supported by MIUR-EU funds (PON 01_02834
and PRIN 2011/13).
Frontiers in Physiology | www.frontiersin.org 10 August 2016 | Volume 7 | Article 354
Spina et al. hDPSCs with Standard and NZ Sera
REFERENCES
Almushayt, A., Narayanan, K., Zaki, A. E., and George, A. (2006). Dentin matrix
protein 1 induces cytodifferentiation of dental pulp stem cells into odontoblasts.
Gene Ther. 13, 611. doi: 10.1038/sj.gt.3302687
Arthur, A., Rychkov, G., Shi, S., Koblar, S. A., and Gronthos, S. (2008).
Adult human dental pulp stem cells differentiate toward functionally active
neurons under appropriate environmental cues. Stem Cells. 26, 1787. doi:
10.1634/stemcells.2007-0979
Bruderer, M., Richards, R. G., Alini, M., and Stoddart, M. J. (2014). Role and
regulation of RUNX2 in osteogenesis. Eur. Cell. Mater. 28, 269–286.
Caplan, A. I. (2007). Adult mesenchymal stem cells for tissue engineering
versus regenerative medicine. J. Cell. Physiol. 213, 341–347. doi: 10.1002/
jcp.21200
d’Aquino, R., De Rosa, A., Lanza, V., Tirino, V., Laino, L., Graziano, A., et al.
(2009). Human mandible bone defect repair by the grafting of dental pulp
stem/progenitor cells and collagen sponge biocomplexes. Eur. Cell. Mater. 18,
75–83.
d’Aquino, R., Graziano, A., Sampaolesi, M., Laino, G., Pirozzi, G., De Rosa, A.,
et al. (2007). Human postnatal dental pulp cells codifferentiate into osteoblasts
and endotheliocytes: a pivotal synergy leading to adult bone tissue formation.
Cell Death Differ. 14, 1162. doi: 10.1038/sj.cdd.4402121
d’Aquino, R., Tirino, V., Desiderio, V., Studer, M., De Angelis, G. C., Laino, L.,
et al. (2011). Human neural crest-derived postnatal cells exhibit remarkable
embryonic attributes either in vitro or in vivo. Eur. Cell. Mater. 21, 304–316.
Desiderio, V., Tirino, V., Papaccio, G., and Paino, F. (2014). Bone defects:
molecular and cellular therapeutic targets. Int. J. Biochem. Cell Biol. 51, 75. doi:
10.1016/j.biocel.2014.03.025
Ferro, F., Spelat, R., Beltrami, A. P., Cesselli, D., and Curcio, F. (2012).
Isolation and characterization of human dental pulp derived stem cells
by using media containing low human serum percentage as clinical grade
substitutes for bovine serum. PLoS ONE. 7:e48945. doi: 10.1371/journal.pone.
0048945
Giuliani, A., Manescu, A., Langer, M., Rustichelli, F., Desiderio, V., Paino, F., et al.
(2013). Three years after transplants in human mandibles, histological and in-
line holotomography revealed that stem cells regenerated a compact rather than
a spongy bone: biological and clinical implications. Stem Cells Transl. Med. 2,
316. doi: 10.5966/sctm.2012-0136
Jiang, L., Zhu, Y. Q., Du, R., Gu, Y. X., Xia, L., Qin, F., et al. (2008). The expression
and role of stromal cell-derived factor-1alpha-CXCR4 axis in human dental
pulp. J. Endod. 34, 939. doi: 10.1016/j.joen.2008.05.015
Kim, D. S., Kim, Y. S., Bae, W. J., Lee, H. J., Chang, S. W., Kim, W. S., et al. (2013).
The role of SDF-1 and CXCR4 on odontoblastic differentiation in human dental
pulp cells. Int. Endod. J. 47, 534. doi: 10.1111/iej.12182
Laino, G., d’Aquino, R., Graziano, A., Lanza, V., Carinci, F., Naro, F., et al. (2005).
A new population of human adult dental pulp stem cells: a useful source of
living autologous fibrous bone tissue (LAB). J. Bone Miner. Res. 20, 1394. doi:
10.1359/JBMR.050325
Lamalice, L., Le Boeuf, F., and Huot, J. (2007). Endothelial cell migration during
angiogenesis. Circ. Res. 100, 782. doi: 10.1002/dvdy.22389
La Noce, M., Paino, F., Spina, A., Naddeo, P., Montella, R., Desiderio, V.,
et al. (2014). Dental pulp stem cells: state of the art and suggestions
for a true translation of research into therapy. J. Dent. 42, 761. doi:
10.1016/j.jdent.2014.02.018
Mackensen, A., Dräger, R., Schlesier, M., Mertelsmann, R., and Lindemann, A.
(2000). Presence of IgE antibodies to bovine serum albumin in a patient
developing anaphylaxis after vaccination with human peptide-pulsed dendritic
cells. Cancer Immunol. Immunother. 49, 152. doi: 10.1007/s002620050614
Mele, L., Vitiello, P. P., Tirino, V., Paino, F., De Rosa, A., Liccardo, D., et al.
(2016). Changing paradigms in cranio-facial regeneration: current and new
strategies for the activation of endogenous stem cells. Front. Physiol. 7:62. doi:
10.3389/fphys.2016.00062
Mitsiadis, T. A., Feki, A., Papaccio, G., and Catón, J. (2011). Dental pulp stem
cells, niches, and notch signaling in tooth injury. Adv. Dent. Res. 23:275. doi:
10.1177/0022034511405386
Naddeo, P., Laino, L., La Noce, M., Piattelli, A., De Rosa, A., Iezzi, G.,
et al. (2015). Surface biocompatibility of differently textured titanium
implants with mesenchymal stem cells. Dent. Mater. 31, 235–243. doi:
10.1016/j.dental.2014.12.015
Neve, A., Corrado, A., and Cantatore, F. P. (2013). Osteocalcin: skeletal and
extra-skeletal effects. J. Cell. Physiol. 228, 1149. doi: 10.1002/jcp.24278
Paino, F., Ricci, G., De Rosa, A., D’Aquino, R., Laino, L., Pirozzi, G., et al. (2010).
Ecto-mesenchymal stem cells from dental pulp are committed to differentiate
into active melanocytes. Eur. Cell. Mater. 20, 295–305.
Ponnaiyan, D., Bhat, K. M., and Bhat, G. S. (2012). Comparison of immuno-
phenotypes of stem cells from human dental pulp and periodontal ligament.
Int. J. Immunopathol. Pharmacol. 25, 127–134.
Sundin, M., Ringdén, O., Sundberg, B., Nava, S., Götherström, C., and Le
Blanc, K. (2007). No alloantibodies against mesenchymal stromal cells,
but presence of anti-fetal calf serum antibodies, after transplantation in
allogeneic hematopoietic stem cell recipients. Haematologica 92, 1208–1215.
doi: 10.3324/haematol.11446
Tirino, V., Paino, F., De Rosa, A., and Papaccio, G. (2012). Identification, isolation,
characterization, and banking of human dental pulp stem cells. Methods Mol.
Biol. 879, 443–463. doi: 10.1007/978-1-61779-815-3_26
Zhang, W., Walboomers, X. F., Shi, S., Fan, M., and Jansen, J. A. (2006).
Multilineage differentiation potential of stem cells derived from human dental
pulp after cryopreservation. Tissue Eng. 12, 2813. doi: 10.1089/ten.2006.12.2813
Zhou, X., Zhang, Z., Feng, J. Q., Dusevich, V. M., Sinha, K., Zhang, H., et al.
(2010). Multiple functions of Osterix are required for bone growth and
homeostasis in postnatal mice. Proc. Natl. Acad. Sci. U.S.A. 107, 12919. doi:
10.1073/pnas.0912855107
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
The handling Editor declared a collaboration with one of the authors TM
and states that the process nevertheless met the standards of a fair and objective
review.
Copyright © 2016 Spina, Montella, Liccardo, De Rosa, Laino, Mitsiadis and La Noce.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) or licensor are credited and that the
original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply
with these terms.
Frontiers in Physiology | www.frontiersin.org 11 August 2016 | Volume 7 | Article 354
